

## DESENSITIZATION OF METHYLPHENIDATE – INDUCED BEHAVIORAL SENSITIZATION IN RATS TREATED WITH MODAFINIL

Muhammad Farhan<sup>\*1</sup>, Sana Wali<sup>1</sup>, Hamna Rafiq<sup>1</sup>, Fatima Riaz<sup>1</sup> and Darakshan Jabeen Haleem<sup>2</sup>

<sup>1</sup>Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Karachi, Pakistan.

<sup>2</sup>Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan

\*Email: farhankamali@uok.edu.pk

\*Correspondence: Email: farhankamali@uok.edu.pk

---

### ABSTRACT

Behavioral sensitization is the phenomenon described as the repetitive, infrequent drug administration that leads to a progressive increase in a response to that drug over time and defined as augmented locomotion. Behavioral sensitization can smoothly be measured in animals by defining alternation in their locomotion in a drug response. Methylphenidate is an inhibitor of dopamine transporter and profound for the therapeutics of associated with attention deficit hyperactivity, but it has been reported that long term usage can cause addiction and dependency. It develops locomotor sensitization. Modafinil is an innovative agent that promotes attentiveness and alertness. It localized wakefulness areas concerning drug-induced neuronal activation via an action on oradrenergic neurotransmission. This preclinical work was intended in order to explore the consequences of agents like modafinil pretreatment on methylphenidate influenced behavioral sensitization. The results determined that doses 1, 2 and 4 mg/kg of methylphenidate produce an induction in activity in an activity box and open field as antidepressant-like effect and reduction of anxiogenesis novel environment. Further modafinil pretreatment for two weeks followed by daily co treatment of methylphenidate prevents locomotor sensitization in laboratory animals. Results obtained demonstrated that the increase of modafinil-induced behavioral sensitization is independent on direct neuro adaptive variations in D1 and D2 dopaminergic receptors. This study, therefore establish the correlation between methylphenidate and modafinil and their effect on locomotor sensitization in rats.

**Keywords:** Behavioral Sensitization, Methylphenidate, Modafinil, Locomotion, Dopaminergic Receptors.

---

### INTRODUCTION

Behavioral sensitization is described as repetitive, irregular drug administration that leads to a progressive increase in a response to that drug over time (Post, 1980; Post and Rose, 1976; Robinson, 1993; Segal and Mandell, 1974). Tolerance is a common physiological response to chronic drug management that is, drug effects commonly reduced with repetitive usage, requiring increasing drug dose to reach the same endpoint (Ramsay and Woods, 1997). Body adapts drug-induced changes by triggering responses that bring all transformed parameters back toward the pre-drug level. The vital principle of homeostasis is these adaptations. The contradictory response pattern occurs regarding sensitization whereby the body's reaction increases with the same dose of drug, or each time involves less drug to reach the same endpoint. This phenomenon seems to be in desecration of homeostatic codes. Behavioral sensitization is dissimilar phenomenon from tolerance, in fact, profligate and non-adaptive (Woods and Ramsay, 2000).

Behavioral sensitization is described as increased in speed, amount and organization of locomotor activity in laboratory animals (Segal and Mandell, 1974). By investigating variations in their induced locomotor activity, behavioral sensitization can smoothly be measured in rodents in response to a drug. Locomotor activity is a consistent and measurable index to quantify sensitization (increased reacting) over the course of drug treatment as it is effortlessly measured in activity observers and demonstrates that a change in behavior has occurred (Eilam and Szechtman, 1989; Einat and Szechtman, 1993).

Methylphenidate is a dopamine transporter inhibitor and used as therapeutic agent for ADHD (attention deficit hyperactivity disorder), however, chronic usage is often reported compulsion and dependence. Methylphenidate develops locomotor sensitization which is a primary effect of drug abuse manifested by psychostimulants. Dopaminergic neurotransmission enhances in the region of brain, neocortex by Methylphenidate (Berridge *et al.*, 2006). It inhibits the dopamine transporter (Ferris and Tang., 1979; Kollins *et al.*, 2001; Barrett *et al.*, 2005) thus increases extra cellular concentration of dopamine and this act initiates molecular episode that strengthens drug seeking behavior, eventually concluding in addiction (Teter *et al.*, 2006; Alizadeh and Ghabili, 2008).

It is reported that the acute dose of Methylphenidate produces hyperactivity in rodents which further sustained with its repeated administration (Castellanos and Tannock, 2002; Rubia *et al.*, 2010; Schecklmann *et al.*, 2010). It has been observed that the behavioral sensitization is mainly associated with the metabolism of dopaminergic system (Kalivas *et al.*, 1993a, 1993b). The consumption history of psycho stimulant was directly correlated with dopamine release, suggesting an augmented response of dopamine with recurrent use of drug (Cox *et al.*, 2009). For the varied physiological functions regulation, the stimulation of D2 dopamine receptor is critical, like control of locomotor activity (Picetti *et al.*, 1997). Serotonergic neurotransmission has been seen to reduce the effect of dopaminergic action in different brain regions like the mid brain and the terminal region (Haleem, 2006).

Modafinil (MOD) is a novel agent that promotes surveillance and has been recommended for the treatment of narcolepsy daytime sleepiness by U.S.A (Food and Drug Administration) FDA. MOD has been considered as an atypical central stimulant compound (Edgar and Seidel, 1997), and is categorized presently as a Schedule IV controlled substance. As the usage of MOD for nonmedical purposes is being prolonged, it has been considered essential to have additional control of the abusive prospective of this drug. Psycho-activity of MOD is advanced than that of caffeine. Whereas, abused psycho-stimulants, for example, cocaine and amphetamine have more of an addictive potential than that of MOD (Dackis *et al.*, 2005; Jasinski, 2000; Karila *et al.*, 2008). The specific mechanism of this MOD is still unknown despite the escalating clinical indications. By using *in vivo* and *in vitro* studies, number of evidences reported modulation of multiple neurotransmitter systems such as serotonin, catecholamines, glutamate, GABA, histamine and orexin and others are the possible mechanisms for the action of modafinil (Ballon and Feifel, 2006; Wisor and Eriksson, 2005). It has been widely seen that MOD, rather than amphetamine, is more localized in the wakefulness regions in terms of drug-induced neuronal activation (Scammell *et al.*, 2000).

Many experiments suggest that modafinil stimulates waking via an action on noradrenergic neurotransmission. Certainly, the waking effect of modafinil in cats, mice, and monkeys is prevented or attenuated by pretreatment with  $\alpha 1$  or  $\beta$  antagonists (Battisti *et al.*, 1999; Deroche-Gamonet *et al.*, 2002). Modafinil could also induce waking by its action on dopamine transmission. Indeed, it demonstrates weak affinity for the dopamine transporter (DAT) and does not enhance waking in mice with deletion of the DAT gene (Edgar and Seidel, 1997). Modafinil does not induce abnormal behavior alteration, tolerance, sensitization, or reinforcing properties unlike psychostimulants such as amphetamine and methylphenidate that act on dopamine neurotransmission (Chenet *et al.*, 2007; Engber *et al.*, 1998). Moreover, modafinil is well demonstrated to induce wakefulness without escalating locomotor activity or consequent hyper-somnolence rebound (Ferraro *et al.*, 1996; Goeders, 2003). Therefore, the purpose of the present study was to investigate the effects of pretreatment with modafinil in rats showing methylphenidate induced behavioral sensitization.

## METHODS

### Animals

The study was conducted on male rats (Albino Wistar), weight of  $160 \pm 10$  grams, were acquired from The Dow University of Health Sciences Karachi, Pakistan (DUHS). Animals were allowed to acclimatize with their surroundings in individual cages for one week in controlled environment. Animals had free access to normal standard diet and drinking water during this period.

### Drugs

Methylphenidate-HCl (Sigma, St Louis, Missouri, USA) was prepared in saline daily before injection and freshly prepared drug were injected in animals subcutaneously. Control animals were administered with saline (1.0 ml/kg) whereas test animals were administered with Modafinil, (dissolved in saline) orally (100mg/kg/day).

### Experiment # 1: Study of Effects of Methylphenidate on Motor Activity in Rats.

Effects of methylphenidate on motor behavior at dose (1.0, 2.0, and 4.0 mg/kg) were found out in familiar and novel environment test was performed to determine a specific dose that induced a sub-maximal increase in motor activity and can be used to monitor behavioral sensitization and its modulation by modafinil. Animals of respective groups ( $n=6$ ) were injected subcutaneously with saline or drug. The behavior in an activity cage was monitored for 10 min (5min post-injection) and open-field activity was monitored for 5 min (30 min post-injection); in the period between the two tests (15 min), animals were kept in their home cages.

### Experiment # 2: MPD Sensitization in MOD Pre-Treated Animals.

Twenty four rodents with an average weight ( $160 \pm 10$ ) were randomly divided into two equal groups, each group was contained 12 rats: (a) saline, (b) 100 mg/kg/day modafinil, injected groups. Saline or modafinil was

administered orally at 10:00–11:00 h in the morning. Modafinil administration lasted for 7 days, during which locomotor activity in familiar and novel area was monitored on next day 1<sup>st</sup> and 7<sup>th</sup> day of administration. Subsequently, modafinil and methylphenidate (1.0 mg/kg) co-treatment was started on day 9. Animals of each group divided randomly into saline-injected or methylphenidate-injected subgroups were injected accordingly at 11:00–12:00 h immediately after administration of saline or modafinil for next 7 days. Motor activity in was monitored after 24 hrs of of 1<sup>st</sup> and 7<sup>th</sup> day of methylphenidate or saline administrations.

### Experiment #3: Expression of MPD Sensitization in MOD-Treated Animals

Rats were divided into four groups (eight rats in each group): (a) saline, (b) methylphenidate, (c) modafinil and methylphenidate, and (d) modafinil pre-treated before co-treatment with modafinil and methylphenidate. Animals in the modafinil-pretreated group were administered with modafinil (100 mg/kg) for 7 days. The other three groups received with saline pretreatment during this period. Subsequently, various groups were treated accordingly with saline, methylphenidate (1.0 mg/kg), or methylphenidate (1.0 mg/kg) plus modafinil (100 mg/kg) daily for 7 days. On 7<sup>th</sup> day, all groups were injected with methylphenidate (1.0 mg/kg) at 09:00–10:00 h to monitor motor activity in an activity cage (5 min post-injection) and open field (30 min post-injection).

## ACTIVITY MONITORING

### a. ACTIVITY CAGE TEST (HOME CAGE)

The motor behavior of animal in a familiar environment was assessed by activity box test. Activity box was a Perspex square shaped cage of equal dimensions like 26 x 26 x 26 cm. The apparatus floor is bedded with saw dust. Animal was observed in a quiet room under white light. Rats were placed in the activity box for 15 minutes for habituation. Activity was monitored in terms of number of crossing across the cage in all direction with the cutoff time 10 minutes.

### b. OPEN FIELD ACTIVITY TEST

To determine the activity of animal in novel environment, open field activity apparatus was used, from which escape is prevented by the surrounding wall. The apparatus of open field used in this experiment was made up of transparent Plexiglas having square area of dimensions 76 x 76 cm with opaque walls of 42 cm height. The floor of the apparatus is divided by lines drawn on the floor into 25 equal squares. For the determination of activity animal was allowed to place in the center square part of the apparatus. The time required by rats to move from the center of the apparatus was monitored and the activity (number of square crossed with all four paws) was monitored for 5 minutes.

## Statistical analysis

Data on dose-dependent effects of methylphenidate on activity in the activity cage or open field and on methylphenidate induced hyper-locomotion in repeated saline, repeated methylphenidate, and repeated methylphenidate plus modafinil-injected animals were examined by One-Way (ANOVA) SPSS version 15.0. Data on the activity of modafinil administrations for 7 days determined by two-way ANOVA (repeated-measures) ANOVA. Data of methylphenidate administration with modafinil and saline pretreated rats were analyzed by three-way repeated-measures ANOVA. For to perform Post-hoc analysis Newman-Keuls test was used.

## RESULTS

**Figure 1** explains the effect of repeated dose of methylphenidate (1.0 mg/kg) on motor activity in an activity box as well as in open field of Albino-Wistar rats. Results of the data (a) on number of cage crossed by one-way ANOVA showed significant effects of methylphenidate administration ( $F=33.125$ ;  $df=3, 20$ ;  $p < 0.01$ ). Post-hoc analysis by Newman-Keuls test showed that administration of methylphenidate increased the activity in activity box (number of cage crossing) significantly ( $p < 0.01$ ) at all doses 1.0, 2.0 and 4.0 mg/kg as compared to saline injected controls. Analysis of the data (b) on number of square crossed in open field by one-way ANOVA (repeated measure design) showed significant effects of methylphenidate ( $F=23.669$ ;  $df=3, 20$ ;  $p < 0.01$ ) on number of square crossed in open field test. Post-hoc analysis by Newman-Keuls test showed that methylphenidate administered at dose 1.0, 2.0 and 4.0 mg/kg greater the number of square crossings significantly ( $p < 0.01$ ) as compared to saline injected controls.

**Figure 2** explains the effects of repeated dose of modafinil (100 mg/kg) on activity in a cage box and an open field of male Albino-Wistar rats monitored on next day of 1<sup>st</sup> and 7<sup>th</sup> day of administrations. Analysis of the data (a)

on number of cage crossed by two-way ANOVA (repeated measure designing) showed significant effects of repeated monitoring ( $F=54.33$ ;  $df=1, 22$ ;  $p < 0.01$ ), effects of modafinil administration ( $F=84.26$ ;  $df=1, 22$ ;  $p < 0.01$ ) and interaction between repeated monitoring and modafinil administration ( $F=180.08$ ;  $df=6, 22$ ;  $p < 0.01$ ). Newman-Keuls test showed that number of cage crossed increase in modafinil administrated animals as compare to water administrated animals. The activity was significantly increases ( $p < 0.01$ ) in after 7<sup>th</sup> day of administration ( $p < 0.01$ ). Modafinil induced sensitization was elevated ( $p < 0.01$ ) on repeated doses than single. Data (b) on number of square crossed by two way ANOVA (repeated measure designing) showed significant effects of repeated monitoring ( $F=154.36$ ;  $df=1,22$ ;  $p < 0.01$ ) and effects of modafinil ( $F=492.47$ ;  $df=1,22$ ;  $p < 0.01$ ) were significant. The interaction between modafinil and repeated monitoring ( $F=9.070$ ;  $df=1,22$ ) was non-significant. Newman-Keuls test showed that modafinil administration increased exploratory activity in open field than water administrated control. Significant increase was found after 1<sup>st</sup> ( $p < 0.05$ ) and 7<sup>th</sup> ( $p < 0.01$ ) day of administration. Hyper-locomotion effect of modafinil was greater ( $p < 0.01$ ) on repeated administrated animals as compared to acute.




Fig. 1 Dose-related effects of methylphenidate (0-4 mg/kg) on activity in an activity box (a) and an open field (b). Values are mean  $\pm$ SD ( $n=6$ ); \* $p < 0.01$  from saline-injected animals following one-way ANOVA.

**Figure 3** explains the effect of repeated dose of methylphenidate (1.0mg/kg) on activity in an activity cage box and in open field of rats pre-treated with modafinil for 7 days which were monitored on next day of 1<sup>st</sup> and 7<sup>th</sup> day of administrations. Analysis of the data on number of cage crossed by three-way ANOVA (repeated measure designing) showed significant effects of repeated monitoring ( $F=196.36$ ;  $df=1, 22$ ;  $p < 0.01$ ), effects of methylphenidate administration ( $F=86.62$ ;  $df=1, 22$ ;  $p < 0.01$ ) and interaction between repeated monitoring and

modafinil treatment ( $F=180.08$ ;  $df=1, 22$ ;  $p < 0.01$ ). However, the effects of modafinil ( $F=5.158$ ;  $df=1, 22$ ) was found non-significant. Post-hoc analysis by Newman-Keuls test showed that methylphenidate at dose 1.0 mg/kg produced behavioral sensitization on repeated administration in saline treated controls as compared to saline administrated animals. Whereas, in modafinil treated animals, sensitization induced by methylphenidate was attenuated. Increased in number of cage crossing was greater after 5<sup>th</sup> ( $p < 0.05$ ), 6<sup>th</sup> and 7<sup>th</sup> ( $p < 0.01$ ) days of administration. Hyper-locomotive action of methylphenidate was higher ( $p < 0.01$ ) after 4<sup>th</sup> till 7<sup>th</sup> day of administrations in saline treated controls. In modafinil treated animals, decreased in activity was significant ( $p < 0.01$ ) from 5<sup>th</sup> to 7<sup>th</sup> day of methylphenidate administrations. Analysis of the data (b) on number of square crossed in open field by three-way ANOVA (repeated measure designing) showed significant effects of methylphenidate ( $F=71.282$ ;  $df=1, 22$ ;  $p < 0.01$ ), effects of repeated monitoring ( $F=137.169$ ;  $df=1, 22$ ;  $p < 0.01$ ) and interaction between repeated monitoring and modafinil administration ( $F=75.413$ ;  $df=1, 22$ ;  $p < 0.01$ ) but the effects of modafinil ( $F=0.017$ ;  $df=1, 22$ ) was found non-significant. Post-hoc analysis by Newman-Keuls test showed that methylphenidate induced hyper-exploratory activity was greater after 7<sup>th</sup> day of administration ( $p < 0.01$ ) as compared to saline control as well as similarly methylphenidate administrated animals of 1<sup>st</sup> day administration. In modafinil pre-treated animals, methylphenidate induced hyper exploratory activity was attenuated after single as well as repeated administration. Significant decreased in activity was found after 7<sup>th</sup> day of administration ( $p < 0.01$ ).




Fig. 2. Effects of administration of MOD (1.0 mg/kg/day) on activity in an activity box (a) and an open field (b). Values are means  $\pm$  SD ( $n=12$ ) as monitored on next day of every drug of administration. Significant differences by Newman-Keuls test: \*  $p < 0.01$  from respective water treated controls; + $p < 0.01$  from respectively 1<sup>st</sup> day MOD treated animals, following two-way ANOVA (repeated measures design).




Fig. 3(a). Effects of administration of MPD (1.0 mg/kg) on activity in activity box of MOD pre-treated animal. Values are means  $\pm$  SD (n=12) as monitored on next day of every drug of administration. Significant differences by Newman-Keuls test: \* $p < 0.05$ , \*\*  $p < 0.01$  from respective saline injected controls; + $p < 0.01$  from respective 1<sup>st</sup> day MPD injected animals, following the-way ANOVA (repeated measures design).

**Figure 4** explains the effect of methylphenidate at dose 1.0 mg/kg on activity in a cage box and an open field of male Albino-Wistar rats treated repeatedly with saline, methylphenidate, methylphenidate and modafinil, co-treated with methylphenidate and modafinil following modafinil treatment. Results of data (a) on number of cage crossed by one-way variance (repeated measure designing) showed significant effects of treatment ( $F=151.507$ ;  $df=3, 20$ ;  $p < 0.01$ ) on activity in cage box. Newman-Keuls test indicates that methylphenidate induced hyper locomotion was greater ( $p < 0.01$ ) in repeatedly treated methylphenidate and repeatedly methylphenidate plus modafinil co-treated animals as compared to saline administrated animals. Whereas, decreased in numbers of cage crossed were found in co-treated repeatedly with methylphenidate plus modafinil following modafinil pretreated animals ( $p < 0.05$ ). Methylphenidate administration increased number of cage crossing were smaller ( $p < 0.01$ ) in repeatedly methylphenidate plus modafinil co-treated as well as co-treated repeatedly treated with methylphenidate plus modafinil following pretreated animals. Analysis of the data (b) on number of square crossed by one-way ANOVA showed significant effects of treatment ( $F=44.962.507$ ;  $df=3, 20$ ;  $p < 0.01$ ) on activity in open field. Newman-Keuls test indicates that administration of methylphenidate increased activity in open field was greater ( $p < 0.01$ ) in repeatedly treated methylphenidate animals but decreased activity were found in repeatedly methylphenidate plus modafinil co-treated animals and co-treated repeatedly treated with methylphenidate plus modafinil following modafinil pretreated animals ( $p < 0.05$ ) as compared to saline administrated animals. Methylphenidate induced hyper-exploratory activity were smaller ( $p < 0.01$ ) in repeatedly methylphenidate plus modafinil co-treated as well as co-treated repeatedly treated with methylphenidate plus modafinil following pretreated animals.




Fig. 3(b). Effects of administration of MPD (1.0 mg/kg) on activity in an open field of MOD pre-treated animal. Values are means  $\pm$  SD (n=12) as monitored on next day of every drug of administration. Significant differences by Newman-Keuls test: \*  $p < 0.01$  from respective water treated controls; + $p < 0.01$  from respective 1<sup>st</sup> day MOD treated animals, following two-way ANOVA (repeated measures design).

## DISCUSSION

Behavioral sensitization is a condition which is caused by the repeated administration of a drug of abuse to produce continuous increased action in the locomotion of the drug during the repeated exposure phase and in response to acute drug challenge after a drug-free ('withdrawal') period. Induction in locomotor activity which is a consequence of alternating administration of drug abuse. In direct methods of abuse-related characteristics of drugs provide locomotor sensitization and drug differentiation (Neil *et al.*, 2010). The proposed present study suggests that MOD impact was about to change the alteration taking after dull act of dopaminergic D1/D2 receptors. MPD, as other pivotal stimulants, share basic systems of activity. The outcomes confirmed that MOD in vigilance advancing measurements empowered locomotive action of the rat to be sensitized and this was exceptional in contrast to the routine dopaminergic D1/D2 receptor agonist, for example, MPD. MOD refining locomotive exercises in an action encircle and an open field was measured subsidiary. Repeated administrations of both MOD and MPD brought about modification. Cross-sensitization was not observed in MPD experiments in rats that had demonstrated sensitization to MOD. Strikingly, cross-sensitization complications occurred in MOD, rats effectively sensitive to MPD.

From the first part of the present study, the results indicates that recommended doses of MPD increased the behavior of rats in activity and open field apparatus. MPD at different doses) 1.0, 2.0 and 4.0 mg/kg) used in this present study produces comparable effects on motor behavior in different behavioral models in a dose dependent manner (figure 1). It was found that higher (1.0 mg/kg) doses of MPD elicit behavioral sensitization concluding that these doses may exacerbate impulsivity in ADHD patients with chronic treatment of drug.




Fig. 4. Effects of administration of MPD (1.0 mg/kg) on activity in an activity box and open field of rats treated with saline, methylphenidate, methylphenidate and modafinil and methylphenidate with co-treated modafinil following modafinil pretreatment. Values are means  $\pm$  SD (n=6) as monitored on next day of every drug of administration. Significant differences by Newman-Keuls test: \*p < 0.05, \*\* p < 0.01 from respective saline treated controls; +p < 0.01 from respective repeated methylphenidate administrated animals following two-way ANOVA (repeated measures design).

Repeated exposure to psychostimulants elicit behavioral sensitization demonstrated by Behavioral experiments in laboratory. The progressive augmentation of the initial, behavioral responses to a psychostimulant refers to behavioral sensitization (Leith and Kuczenski, 1982; Kalivas and Stewart, 1991; Wolf 1998). The recurrent treatment of a low dose of the psychostimulant provoked a sensitized reaction to a psychostimulant, while higher doses produce tolerance (Leith and Kuczenski, 1982; Robinson and Berridge, 1993). Recurring administration of amphetamine, methamphetamine and cocaine stimulates behavioral sensitization (Robinson and Becker, 1986; Segal and Kuczenski, 1987; Pierce and Kalivas, 1997; Crawford *et al.*, 1998). Whereas, outcomes of behavioral sensitization resulted from repeated experience of MPD have been unpredictable (McNamara *et al.*, 1993; Gaytan *et al.*, 1997a; Izenwasser *et al.*, 1999; Kuczenski and Segal, 2002; Yang *et al.*, 2003). Many studies suggest a sensitized locomotor response to methylphenidate take place succeeding repeated administration (Yang *et al.*, 2007; Wooters *et al.*, 2007). The present work demonstrates the development of a sensitized motor response to MPD in an

activity cage as well as in an open field. The main finding of the present study is the sensitized motor response to MPD was not exerted in animals pretreated and co-treated with MOD. Studies determined that psychostimulants generate variations in the release characteristics of DA (Robinson *et al.*, 1988; Kalivas and Duffy, 1990; Vezina 1993) DA-stimulated signal transduction mechanisms alternations (Steketee *et al.*, 1991; Steketee 1994; Miserendino and Nestler, 1995). Locomotor and neurophysiological sensitization are affected by these drugs changes.

Results from the present study illustrated that the treatment of modafinil for two weeks increased the activity of rats in activity cage (Figure 2a). The exploratory activity of rats in open field (Figure 2b) exacerbates following repeated administration of MOD. An increase in open field exploration and in an activity box in MOD-treated animals likely indicates an antidepressant-like effect and reduction of novelty-induced anxiety.

The present work demonstrates that the pretreatment of modafinil for 2 weeks followed by daily co-treatment of MPD with MOD actually prevents locomotor sensitization to MPD, rather than MOD merely blocking the expression of motor effects of MPD. This is shown by the absence of a sensitized locomotor response to MPD when these rats received an injection of MPD only (Fig. 4). Interestingly, rats receiving MOD, but without the previous 2 weeks of MOD pretreatment, also showed a sensitized locomotor response on the test for sensitization to MPD (Fig. 4).

In summary, our study demonstrated that MOD-induced behavioral sensitization seemed to be independent on direct neuroadaptive changes in D1 and D2 dopaminergic receptors. The treatment of MOD needs caution because of its potency to develop addiction. MPD-pretreated rats showed cross-sensitization to MOD challenges. However, MOD induced stimulation of behavior was less than that induced by MPD indicates that MOD may be useful for medication of addiction or withdrawal symptoms induced by other psychostimulants.

## REFERENCES

- Alizadeh, M. and K. Ghabili (2008). Health related life style among the Iranian medical students. *Res. J. Biol. Sci.*, 3: 4-9.
- Ballon, J.S. and D. Feifel (2006). A systematic review of modafinil: Potential clinical uses and mechanisms of action. *J. Clin. Psychiatry*, 67: 554-566.
- Barrett, S.P., C. Darredeau, L.E. Bordy and R.O. Pihl (2005) Characteristics of methylphenidate misuse in a university student sample. *Can J. Psychiatry*, 50: 457- 461.
- Battisti, J.J., N.U.J. retsky and L. J. Wallace (1999). Sensitization of apomorphine-induced stereotyped behavior in mice is context dependent. *Psychopharmacology* (Berl), 146: 42-48.
- Berridge, D.M. Devilbiss, M.E. Andrzejewski, A.F. Arnsten, A.E. Kelley and B. Schmeichel *et al.* (2006). Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. *Biol. Psychiatry*, 60: 1111-1120.
- Castellanos, F.X. and R. Tannock (2002). Neuroscience of attention-deficit/hyperactivity disorder: The search for endophenotypes. *Nat. Rev. Neurosci.*, 3: 617-628.
- Chen, C.R., W.M. Qu, M.H. Qiu, X.H. Xu, M.H. Yao, Y. Urade and Z.L. Huang (2007). Modafinil exerts a dose-dependent antiepileptic effect mediated by adrenergic  $\alpha 1$  and histaminergic H1 receptors in mice. *Neuropharmacology*, 53: 534-541.
- Cox, S.M., C. Benkelfat, A. Dagher, J.S. Delaney, F. Durand, S.A. McKenzie, T. Kolivakis, K.F. Casey and M. Leyton (2009). Striatal dopamine responses to intranasal cocaine self-administration in humans. *Biol. Psychiatry*, 65: 846-850.
- Crawford, C.A., S.A. McDougall, T.L. Meier, R.L. Collins and J.B. Watson (1998). Repeated methylphenidate treatment induces behavioral sensitization and decreases protein kinase A and dopamine-stimulated adenylyl cyclase activity in the dorsal striatum. *Psychopharmacology* (Berl), 136(1): 34-43.
- Dackis, C.A., K.M. Kampman, K.G. Lynch, H.M. Pettinati and C.P. O'Brien (2005). A double-blind, placebo-controlled trial of modafinil for cocaine dependence. *Neuropsychopharmacology*, 30: 205- 211.
- Deroche-Gamonet, V., M. Darnaudery, L. Bruins-Slot, F. Piat, M. Le Moal and P.V. Piazza (2002). Study of the addictive potential of modafinil in naive and cocaine-experienced rats. *Psychopharmacology* (Berl), 161: 387-395.
- Edgar, D.M. and W.F. Seidel (1997). Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. *J. Pharmacol. Exp. Ther.*, 283: 757-769.
- Eilam, D. and H. Szechtman (1989). Biphasic effect of D-2 agonist quinpirole on locomotion and movements. *Eur J Pharmacol.*, 161(2-3): 151-157.

- Einat, H., and H. Szechtman (1993). Environmental modulation of both locomotor response and locomotor sensitization to the dopamine agonist quinpirole. *BehavPharmacol.*, 4(4): 399-403.
- Engber, T.M., S.A. Dennis, B.F. Jones, M.S. Miller and P.C. Contreras (1998). Brain regional substrates for the actions of the novel wake promoting agent modafinil in the rat: comparison with amphetamine. *Neuroscience*, 87: 905-911.
- Ferraro, L., S. Tanganelli, W.T. O'Connor, T. Antonelli, F. Rambert and K. Fuxe (1996). The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. *Eur. J. Pharmacol.*, 306: 33-39.
- Ferris R.M. and F.L.M. Tang (1979). Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypradol on the uptake of 1- [ 3 H] norepinephrine and [3 H] dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus. *J. Pharmacol. Exp. Ther.*, 210: 422- 428.
- Gaytan, O., S. Al-Rahim, A. Swann and N.Dafny (1997). Sensitization to locomotor effects of methylphenidate in the rat. *Life Sci.*, 61(8): 101-7.
- Goeders, N.E. (2003). The impact of stress on addiction. *Eur. Neuropsychopharmacol.*, 13: 435-441.
- Haleem, D.J. (2006). Serotonergic modulation of dopamine neurotransmission: A mechanism for enhancing therapeutics in schizophrenia. *J. Coll. Physicians Surg. Pak.*, 16(8): 556-562.
- Izenwasser, S., A.E. Coy, B. Ladenheim, R.J. Loeloff, J.L. Cadet and D. French (1999). Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. *Eur J Pharmacol.* , 373(2-3): 187-93.
- Jasinski, D.R. (2000). An evaluation of the abuse potential of modafinil using methylphenidate as a reference. *J. Psychopharmacol.*, 14: 53-60.
- Kalivas, P.W., L. Churchill and M.A. Klitenick (1993a). GABA and enkephalin projection from the nucleus accumbens and ventral pallidum to the ventral tegmental area. *Neuroscience*, 57: 1047-1060.
- Kalivas, P.W. and P. Duffy (1990). Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. *Synapse*, 5(1): 48-58.
- Kalivas, P.W., B.A. Sorg and M.S. Hooks (1993b). The pharmacology and neural circuitry of sensitization to psychostimulants. *Behav. Pharmacol.* , 4: 315-334.
- Kalivas, P. W. and Stewart (1991). Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. *J Brain Res Brain Res Rev.*, 16(3): 223-44.
- Kollins, S.H., E.K. MacDonald and C.R. Rush (2001). Assessing the abuse potential of methylphenidate in nonhuman and human subjects: A review. *Pharmacol.Biochem.Behav.* , 68: 611-627.
- Karila, L., D. Gorelick, A. Weinstein, F. Noble, A. Benyamina, S. Coscas, L. Blecha, W. Lowenstein, J.L. Martinot, M. Reynaud and J.P. Lepine (2008). New treatments for cocaine dependence: a focused review. *Int. J. Neuropsychopharmacol.*, 11: 425-438.
- Kuczenski, R. and D.S. Segal (2002). Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. *J.Neurosci.* , 22(16):7264-71.
- Leith, N.J. and R. Kuczenski (1982). Two dissociable components of behavioral sensitization following repeated amphetamine administration. *Psychopharmacology (Berl)* , 76(4): 310-5.
- McNamara, C.G., E.S. Davidson and S. Schenk (1993). A comparison of the motor-activating effects of acute and chronic exposure to amphetamine and methylphenidate. *PharmacolBiochemBehav.* , 45(3): 729-32.
- Miserendino, M.J. and E. J. Nestler (1995). Behavioral sensitization to cocaine: modulation by the cyclic AMP system in the nucleus accumbens. *Brain Res.*, 674(2):299-306.
- Neil, E., Paterson, A. Fedolak, B. Olivier, T. Hanania, A. Ghavami and B. Caldarone (2010). Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. *PharmacolBiochemBehav.*, 95(4): 449-456.
- Picetti, R., A. Saiardi, T. AbdelSamad, Y. Bozzi, J.H. Baik and E. Borrelli (1997). Dopamine D2 receptors in signal transduction and behavior. *Crit. Rev. Neurobiol.*, 11: 121-142.
- Pierce, R.C. and P.W. Kalivas (1997). A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. *Brain Res Brain Res Rev.*, 25(2): 192-216.
- Post, R. M. (1980). Intermittent versus continuous stimulation: Effect of time interval on the development of sensitization or tolerance. *Life Sci*, 26(16): 1275-1282.
- Post, R. M., and H. Rose (1976). Increasing effects of repetitive cocaine administration in the rat. *Nature*, 260(5553): 731-732.
- Ramsay, D. S. and S.C. Woods (1997). Biological consequences of drug administration: Implications for acute and chronic tolerance. *Psychol Rev.*, 104(1): 170-193.

- Robinson, T. E. (1993). Persistent sensitizing effects of drugs on brain dopamine systems and behavior: Implications for addiction and relapse. In: *Biological basis of substance abuse*. S. G. Korenman and J. D. Barchas (Eds.), pp.373-402.
- Robinson, T.E. and J.B. Becker (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. *Brain Res.*, 396(2): 157-98.
- Robinson, T.E. and K.C. Berridge (1993). The neural basis of drug craving: an incentive-sensitization theory of addiction. *Brain Res Brain Res Rev.*, 18(3): 247-91.
- Robinson, T.E., P.A. Jurson, J.A. Bennett and K.M. Bentgen (1988). Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. *Brain Res.*, 462(2): 211-22
- Rubia, K., R. Halari, A. Cubillo, A.B. Smith, A.M. Mohammad, M. Brammer and E. Taylor (2011). Methylphenidate normalizes fronto-striatal under activation during interference inhibition in medication-naïve boys with attention-deficit hyperactivity Disorder. *Neuropsychopharmacology*, 36: 1575-1586.
- Scammell, T.E., I.V. Estabrooke, M.T. McCarthy, R.M. Chemelli, M. Yanagisawa, M.S. Miller and C.B. Saper (2000). Hypothalamic arousal regions are activated during modafinil-induced wakefulness. *J. Neurosci.*, 20: 8620-8628.
- Schecklmann, M, M. Romanos, F. Bretscher, M.M. Plichta, A. Warnke and A.J. Fallgatter (2010). Prefrontal oxygenation during working memory in ADHD. *Journal of Psychiatric Research*, 44(10): 621-628.
- Segal, D.S. and R.Kuczenski (1987). Behavioral and neurochemical characteristics of stimulant-induced augmentation. *Psychopharmacol Bull.*, 23(3): 417-24.
- Segal, D. S. and A.J. Mandell (1974). Long-term administration of d-amphetamine: Progressive augmentation of motor activity and stereotypy. *PharmacolBiochemBehav.*, 2(2): 249-255.
- Steketee, J.D. (1994). Intra-A10 injection of H7 blocks the development of sensitization to cocaine. *Neuroreport*. 6(1): 69-72.
- Steketee, J.D., C.D. Striplin, T.F. Murray and P.W. Kalivas (1991). Possible role for G-proteins in behavioral sensitization to cocaine. *Brain Res.*, 545(1-2):287-91.
- Teter, C.J., S.E. McCabe, K. LaGrange, J.A. Cranford and C.J. Boyd (2006). Illicit use of specific prescription stimulants among college students: Prevalence, motives and routes of administration. *Pharmacotherapy*, 26: 1501-1510.
- Vezina, P. (1993). Amphetamine injected into the ventral tegmental area sensitizes the nucleus accumbens dopaminergic response to systemic amphetamine: an in vivo micro dialysis study in the rat. *Brain Res.*, 605(2): 332-7.
- Wisor, J.P. and K.S. Eriksson (2005). Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. *Neuroscience*, 132: 1027-1034.
- Wolf, M.E. (1998). The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. *ProgNeurobiol.*, 54(6): 679-720.
- Woods, S. C. and D.S. Ramsay (2000). Pavlovian influences over food and drug intake. *Behav Brain Res.*, 110(1-2): 175-182.
- Wooters, T.E., N.M. Neugebauer, C.R. Rush and M.T. Bardo (2007). Methylphenidate enhances the abuse-related behavioral effects of nicotine in rats: intravenous self-administration, drug discrimination, and locomotor cross-sensitization. *Neuropsychopharmacology*, 33: 1137-48.
- Yang, P.B., B. Amini, A.C. Swann and N. Dafny (2003). Strain differences in the behavioral responses of male rats to chronically administered methylphenidate. *Brain Res.*, 971(2): 139-52.
- Yang, P.B., A.C. Swann and N. Dafny (2007). Chronic administration of methylphenidate produces neurophysiological and behavioral sensitization. *Brain Res.*, 1145: 66-80.

(Accepted for publication August 2018)